It Seems Harpoon Therapeutics, Inc. (HARP) Will Go Down. Have Another Big Decline

The stock of Harpoon Therapeutics, Inc. (NASDAQ:HARP) is a huge mover today! The stock decreased 7.73% or $1.35 during the last trading session, reaching $16.12. About 143,049 shares traded or 270.46% up from the average. Harpoon Therapeutics, Inc. (NASDAQ:HARP) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 7 months negative chart setup for the $395.98 million company. It was reported on Sep, 13 by We have $14.67 PT which if reached, will make NASDAQ:HARP worth $35.64M less.

Analysts await Harpoon Therapeutics, Inc. (NASDAQ:HARP) to report earnings on November, 4. After $-0.49 actual earnings per share reported by Harpoon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 14.29 % negative EPS growth.

More notable recent Harpoon Therapeutics, Inc. (NASDAQ:HARP) news were published by: which released: “Urgent Dividend Buy! 5 REITs Ready for 114% Returns – Nasdaq” on July 24, 2019, also with their article: “Zscaler Analysts Say Cybersecurity Stock A ‘Long-Term Winner’ Despite Earnings Setback – Yahoo Finance” published on September 11, 2019, published: “Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers – GlobeNewswire” on April 18, 2019. More interesting news about Harpoon Therapeutics, Inc. (NASDAQ:HARP) were released by: and their article: “Stocks To Watch: Big Pharma, Green Trucks And Jobs Report – Seeking Alpha” published on March 02, 2019 as well as‘s news article titled: “Key events next week – healthcare – Seeking Alpha” with publication date: August 02, 2019.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company has market cap of $395.98 million. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. It currently has negative earnings. The firm has a collaboration agreement with AbbVie Biotechnology Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.